-Live Mint Farmers resisting India's biggest FDI deal are paying a heavy price for their stand In June 2005, the Orissa government signed the country's biggest foreign direct investment deal yet with the South Korean steel manufacturer Posco for a $12 billion (around `65,856 crore) plant near Paradip in the mineral-rich state. Livelihoods in eight existing agricultural and fishing villages were to give way for the project that was intended to be...

-The Telegraph Calcutta: The Bengal government today suggested that panchayat elections be held on May 5 and 8, springing in the high court a surprise that had little new other than the fresh dates. The government's proposal did not address the security concerns of the state election commission that had moved Calcutta High Court on Monday. According to the commission, central forces have to be deployed if the polls are held in two...

-The Indian Express Mumbai: The Bombay High Court on Wednesday granted anticipatory bail to a senior bank official accused of molesting a teenage girl, saying that "he is a high-profile person and has been exposed to humiliation already". Joginder Singh, a deputy general manager with the Oriental Bank of Commerce, was booked by the police for allegedly molesting a 16-year-old girl in the lift of his residential building in Vile Parle on...

-The Economic Times MUMBAI: India's strong stance on minor drug innovations could reverberate in national parliaments and courthouses of the developed world as Australia, the EU and Canada get ready to discuss and ban patent protection for frivolous improvements. A top Australian government body on Wednesday asked for changes in its patent laws relating to drugs saying that the indiscriminate grant of patents to incremental innovations should be checked and that...

-The Hindu The lesson from the Supreme Court ruling on Gleevec is that pharmaceutical multinational corporations need to focus research on genuine innovations rather than on ways to evergreen their patents The much awaited Supreme Court judgment on Gleevec has been delivered. Novartis has failed in reversing the rejection of its patent. And, predictably - like a scratched record - there have been suggestions that pharma investments in India will dry...